<DOC>
	<DOCNO>NCT00376714</DOCNO>
	<brief_summary>GSK233705 high-affinity specific muscarinic receptor ( mAChR ) antagonist develop daily treatment chronic obstructive pulmonary disease ( COPD ) . The long duration action GSK233705 administer via inhalation animal model support potential use once-daily bronchodilator chronic obstructive pulmonary disease .</brief_summary>
	<brief_title>Safety And Tolerability Study In Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Female subject must nonchildbearing potential include premenopausal female Male subject must agree abstain use condom sexual intercourse pregnant lactating female Subject diagnose COPD , define GOLD guideline Body weight great 50kg Subject smoker exsmoker smoke history least 10 pack year ( 1 pack year = 20 cigarette smoke per day 1 year equivalent ) . Subject FEV1/FVC &lt; 0.7 postbronchodilator ( salbutamol ) . Subject FEV1 great equal 80 % predict normal height , age gender inhalation 200 µg salbutamol . Response ipratropium bromide define : Either : An increase FEV1 =12 % =150 mL 2 h follow inhalation 80 ug ipratropium bromide screen visit : documented increase FEV1 =12 % =150 mL 2 h follow inhalation 80 ug ipratropium bromide within 6 month screen increase FEV1 &gt; 6 % &gt; 100ml 2h follow inhalation 80 ug ipratropium bromide screen visit ( order allow potential fluctuation response ipratropium bromide patient know responder ipratropium bromide ) . Capable give write informed consent , include compliance requirement restriction list consent form . Subject available complete study measurement procedure . Subjects past present disease , judge Investigator Medical Monitor , affect outcome study . The subject positive urine drug/ urine alcohol screen . History alcohol/drug abuse dependence within 12 month study : The subject positive pregnancy test . Subject FEV1 great equal 40 % predicted inhalation salbutamol . A positive Hepatitis B Hepatitis C result within 3 month screen The subject participate clinical trial receive drug new chemical entity within 30 day Exposure four new chemical entity within 12 month prior first dose day . Where participation study would result donation blood excess 500 mL within 56 day period The subject donate unit blood within 30 day screening , , intend donate study . Subject claustrophobia may aggravate enter plethysmography cabinet . The subject know allergy hypersensitivity ipratropium bromide , tiotropium bromide , atropine derivative milk protein/lactose . History sensitivity study medication , component thereof history drug allergy , opinion physician responsible , contraindicate participation Subject unable use DISKUS™ device correctly . Subject prostate hypertrophy narrow angle glaucoma . Use prescription drug ( exception allow protocol ) herbal remedy ( e.g . St John 's Wort ) within 48 hour treatment period</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>plethysmography</keyword>
	<keyword>muscarinic receptor antagonist</keyword>
	<keyword>COPD</keyword>
	<keyword>repeat dose</keyword>
</DOC>